Iatridi Fotini, Carrero Juan Jesus, Gall Emilie Cornec-Le, Kanbay Mehmet, Luyckx Valerie, Shroff Rukshana, Ferro Charles J
First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden.
Nephrol Dial Transplant. 2025 Feb 4;40(2):273-282. doi: 10.1093/ndt/gfae209.
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Guideline for Identification and Management of Chronic Kidney Disease (CKD) is a welcome development, coming 12 years after the paradigm-changing 2012 guidelines. We are living in an unprecedented era in nephrology with novel therapies, including sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists, now being proven in multiple randomized controlled clinical trials to reduce both the progression of CKD and cardiovascular morbidity and mortality. The KDIGO 2024 CKD Guideline is aimed at a broad audience looking after children and adults with CKD and provide practical and actionable steps to improve care. This commentary reviews the guideline sections pertaining to the evaluation and risk assessment of individuals with CKD from a European perspective. We feel that despite the last guideline being published 12 years ago, and the fact that the assessment of CKD has been emphasized by many other national/international nephrology, cardiology and diabetology guidelines and societies, the diagnosis and treatment of CKD remains poor across Europe. As such, the KDIGO 2024 CKD Guideline should be seen as an urgent call to action to improve diagnosis and care of children and adults with CKD across Europe. We know what we need to do. We now need to get on and do it.
《肾脏病：改善全球预后（KDIGO）2024年慢性肾脏病（CKD）识别与管理指南》是一项值得欢迎的进展，它在具有变革意义的2012年指南发布12年后问世。我们正生活在肾脏病学的一个前所未有的时代，包括钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽1受体激动剂和非甾体类盐皮质激素受体拮抗剂在内的新型疗法，现已在多项随机对照临床试验中被证明可降低CKD的进展以及心血管疾病的发病率和死亡率。KDIGO 2024年CKD指南面向照顾CKD儿童和成人的广大受众，提供了改善护理的切实可行步骤。本评论从欧洲视角回顾了该指南中与CKD患者评估和风险评估相关的章节。我们认为，尽管上一版指南于12年前发布，且许多其他国家/国际肾脏病学、心脏病学和糖尿病学指南及学会都强调了CKD的评估，但欧洲各地CKD的诊断和治疗情况仍然不佳。因此，KDIGO 2024年CKD指南应被视为一项紧急行动呼吁，以改善欧洲CKD儿童和成人的诊断和护理。我们知道我们需要做什么。现在我们需要着手去做。
